Regenxbio Inc

NASDAQ:RGNX   12:51:05 PM EDT
31.15
-0.48 (-1.52%)
Earnings Announcements

Regenxbio Reports Second Quarter 2022 Financial Results And Recent Operational Highlights

Published: 08/03/2022 21:52 GMT
Regenxbio Inc (RGNX) - Regenxbio Reports Second Quarter 2022 Financial Results and Recent Operational Highlights.
Regenxbio-rgx-314 Program for Treatment of Wet Amd & Diabetic Retinopathy, Being Developed With Abbvie, Remains on Track for First Bla Filing in 2024.
Regenxbio- Reports $682 Million in Cash, Cash Equivalents and Marketable Securities of As of June 30, 2022 With Operational Runway Into 2025.
Qtrly Loss per Share $1.58.
Q2 Earnings per Share View $-1.53 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $32.21 Million
Adjusted EPS is expected to be -$1.42

Next Quarter Revenue Guidance is expected to be $52.71 Million
Next Quarter EPS Guidance is expected to be -$0.89

More details on our Analysts Page.